Johnson & Johnson’s talc settlement collapse has left a measurable mark on the stock: shares fell about 5% the morning after a Texas bankruptcy judge rejected the company’s $10 billion deal in March 2025, and more than a year later the litigation still trades as an “overhang” that analysts say is holding the price back. JPMorgan estimates roughly $10 billion in talc liability is already baked into the share price, with every additional $5 billion equating to about $2 per share.1Yahoo Finance. Judge Rejects Johnson & Johnson’s Talc Settlement
The March 2025 Drop and What Analysts Price In
On March 31, 2025, U.S. Bankruptcy Judge Christopher Lopez denied confirmation of the Red River Talc settlement, the third failed attempt by J&J to channel tens of thousands of talc claims into a court-supervised trust. Shares fell about 5% at the next open.1Yahoo Finance. Judge Rejects Johnson & Johnson’s Talc Settlement
The scale matters less than it sounds. Leerink Partners pointed out that the proposed $8 billion trust (with total payouts of roughly $10 billion over 25 years) came to about 2% of J&J’s roughly $400 billion market capitalization. JPMorgan’s read was more granular: the stock already reflected about $10 billion of talc liability, and each additional $5 billion of exposure would trim roughly $2 per share.1Yahoo Finance. Judge Rejects Johnson & Johnson’s Talc Settlement
By early 2026 the discount was visible in analyst positioning. Ten of 24 analysts rated J&J as “Hold” or worse, and shares traded around $243 against a mean price target of $231. That target-to-price gap was the least favorable observed in recent periods. If the company has to rebuild talc reserves well beyond the $7 billion it reversed in the first quarter of 2025, operating margins could compress and the valuation multiple could slide toward the 16x–17x range.2TIKR. Johnson & Johnson Stock Crosses $94 Billion in Revenue
How the Failed Settlement Flows Through Earnings
The bankruptcy dismissal produced an accounting swing that has distorted year-over-year comparisons. In the first quarter of 2025, J&J reported net earnings of nearly $11 billion, inflated by a one-time reversal of $7 billion in talc reserves the company no longer expected to pay into the settlement trust. A year later, first-quarter 2026 net earnings were $5.2 billion, and the company recorded $300 million in new talc-related charges.3Stock Titan. Johnson & Johnson Quarterly Earnings Report (10-Q)
Management played down the financial significance of the ruling. CFO Joe Wolk told investors after the dismissal that the outcome did not change the company’s financial outlook and pointed to $20 billion in free cash flow generated the prior year.1Yahoo Finance. Judge Rejects Johnson & Johnson’s Talc Settlement J&J said it would return to the tort system to fight the remaining claims rather than appeal the bankruptcy decision.4Johnson & Johnson. Johnson & Johnson to Return to Tort System to Defeat Meritless Talc Claims
Why the Overhang Persists: Verdicts Still Coming
With bankruptcy closed off, individual trial results now drive the exposure investors have to model. Recent verdicts have been large and volatile:
- A Baltimore jury awarded $1.56 billion in December 2025 to a peritoneal mesothelioma plaintiff ($59.8 million compensatory, $1.5 billion punitive), the largest single-plaintiff talc award to date.5Fierce Pharma. Baltimore Jury Orders J&J to Pay $1.5B, Largest Ever Award to Talc Plaintiff
- A California jury returned a $966 million mesothelioma verdict in October 2025. In March 2026 a Los Angeles Superior Court judge vacated $950 million of the punitive damages for insufficient evidence of malice, leaving the $16 million compensatory award intact; plaintiff’s counsel said they would appeal.6Law.com. LA Judge Tosses $950M in Punitive Damages in Talc Verdict
- A 2018 Missouri verdict of $4.7 billion for twelve ovarian cancer plaintiffs was reduced on appeal to $2.1 billion.5Fierce Pharma. Baltimore Jury Orders J&J to Pay $1.5B, Largest Ever Award to Talc Plaintiff
- A Minnesota jury awarded $65.5 million in December 2025 to a 37-year-old woman with cancer in the lining of her lungs.5Fierce Pharma. Baltimore Jury Orders J&J to Pay $1.5B, Largest Ever Award to Talc Plaintiff
J&J counters that it has prevailed in 16 of 17 ovarian cancer cases tried over the past 11 years and previously settled 95% of filed mesothelioma lawsuits.4Johnson & Johnson. Johnson & Johnson to Return to Tort System to Defeat Meritless Talc Claims Roughly 67,000 federal cases remain pending, most of them ovarian cancer claims, so even a low per-case loss rate translates into meaningful aggregate exposure — the arithmetic that keeps the litigation discount attached to the stock.
What Could Move the Stock Next
Three near-term events sit between J&J and any change in how the market prices talc risk.
The first is mediation. In August 2025 the federal MDL judge in New Jersey appointed a Plaintiffs’ Negotiation Committee and ordered the parties into formal mediation before court-appointed mediator Fouad Kurdi. Settlement talks were scheduled for April 13, 2026, though J&J has historically resisted mediation.7Lawsuit Information Center. $2 Billion Verdict in Missouri Motivates J&J to Settle Talcum Powder Lawsuits
The second is bellwether verdicts. Judkins v. Johnson & Johnson was selected as the first federal bellwether in July 2025, and California and Philadelphia scheduled talc trials for 2026.8Darrow.ai. Johnson and Johnson Talc Lawsuit Outcomes in these early trials tend to reset the market’s implied per-case value.
The third is expert testimony. In January and February 2026, retired U.S. District Judge Freda Wolfson, serving as a special master, reaffirmed that plaintiffs’ expert witnesses may testify about the link between talc and ovarian cancer across the roughly 67,000 pending federal cases, rejecting J&J’s effort to exclude that evidence.7Lawsuit Information Center. $2 Billion Verdict in Missouri Motivates J&J to Settle Talcum Powder Lawsuits That ruling clears a significant procedural hurdle for plaintiffs and removes one path J&J had to compress its aggregate exposure.
A Longer-Term Risk: Legislation Targeting the Texas Two-Step
The strategy J&J used to try to cap its liability, a divisional merger under Texas law that isolated talc claims in a subsidiary before filing for Chapter 11, has drawn bipartisan legislative attention. The Ending Corporate Bankruptcy Abuse Act was introduced in July 2024, and a companion bill, the Consumer Protection and Corporate Accountability in Bankruptcy Act, followed in April 2026 with sponsors including Rep. Emilia Sykes and Sen. Sheldon Whitehouse.9Steptoe LLP. Proposed Legislation Targets Texas Two-Step Bankruptcy Tactic10Office of Rep. Emilia Sykes. Rep. Sykes Leads Bipartisan Bicameral Effort to Rein in Corporate Bankruptcy Abuse Neither bill had been enacted as of mid-2026, and the Supreme Court has not reviewed the tactic. For investors, that means the option of another bankruptcy-style resolution remains legally available but has failed three times in court and now carries added political risk if similar cases return to bankruptcy dockets.